Harrow Past Earnings Performance
Past criteria checks 0/6
Harrow's earnings have been declining at an average annual rate of -50.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 22.2% per year.
Key information
-50.1%
Earnings growth rate
-49.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 22.2% |
Return on equity | -34.7% |
Net Margin | -18.7% |
Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Harrow Health prices 8.625% senior notes due 2026
Jun 15Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage
May 28Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings
May 18Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 11Announcing: Harrow Health (NASDAQ:HROW) Stock Increased An Energizing 299% In The Last Three Years
Mar 08Revenue & Expenses BreakdownBeta
How Harrow makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 130 | -24 | 83 | 7 |
30 Sep 23 | 114 | -14 | 72 | 4 |
30 Jun 23 | 103 | -16 | 67 | 3 |
31 Mar 23 | 93 | -18 | 61 | 3 |
31 Dec 22 | 89 | -14 | 58 | 3 |
30 Sep 22 | 88 | -23 | 54 | 6 |
30 Jun 22 | 84 | -24 | 50 | 12 |
31 Mar 22 | 79 | -21 | 45 | 11 |
31 Dec 21 | 72 | -18 | 40 | 11 |
30 Sep 21 | 67 | -10 | 36 | 8 |
30 Jun 21 | 63 | 7 | 33 | 2 |
31 Mar 21 | 52 | 10 | 31 | 3 |
31 Dec 20 | 49 | -3 | 31 | 2 |
30 Sep 20 | 47 | -2 | 31 | 2 |
30 Jun 20 | 45 | -22 | 32 | 2 |
31 Mar 20 | 51 | -24 | 33 | 2 |
31 Dec 19 | 51 | 0 | 33 | 2 |
30 Sep 19 | 50 | 16 | 34 | 2 |
30 Jun 19 | 48 | 25 | 32 | 2 |
31 Mar 19 | 45 | 29 | 31 | 1 |
31 Dec 18 | 41 | 15 | 29 | 1 |
30 Sep 18 | 37 | -6 | 26 | 0 |
30 Jun 18 | 33 | -9 | 25 | 0 |
31 Mar 18 | 30 | -10 | 25 | 0 |
31 Dec 17 | 27 | -12 | 25 | 0 |
30 Sep 17 | 25 | -15 | 25 | 1 |
30 Jun 17 | 24 | -13 | 26 | 1 |
31 Mar 17 | 22 | -20 | 26 | 1 |
31 Dec 16 | 20 | -19 | 25 | 1 |
30 Sep 16 | 18 | -18 | 25 | 0 |
30 Jun 16 | 15 | -18 | 24 | 0 |
31 Mar 16 | 13 | -17 | 21 | 0 |
31 Dec 15 | 10 | -16 | 19 | 0 |
30 Sep 15 | 7 | -14 | 16 | 0 |
30 Jun 15 | 5 | -12 | 13 | 0 |
31 Mar 15 | 3 | -11 | 12 | 0 |
31 Dec 14 | 2 | -10 | 10 | 0 |
30 Sep 14 | 1 | -9 | 10 | 0 |
30 Jun 14 | 1 | -9 | 9 | 1 |
31 Mar 14 | 0 | -9 | 7 | 1 |
31 Dec 13 | 0 | -8 | 6 | 2 |
30 Sep 13 | 0 | -7 | 5 | 2 |
30 Jun 13 | 0 | -6 | 4 | 2 |
Quality Earnings: HROW is currently unprofitable.
Growing Profit Margin: HROW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HROW is unprofitable, and losses have increased over the past 5 years at a rate of 50.1% per year.
Accelerating Growth: Unable to compare HROW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HROW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: HROW has a negative Return on Equity (-34.67%), as it is currently unprofitable.